GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor Signaling

GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor Signaling

GZ17-6.02 (602) is presently under phase I clinical evaluation (NCT03775525). We defined the mechanisms by which it interacted with a standard of care therapeutic doxorubicin to kill sarcoma cells. Doxorubicin and 602 interacted to rapidly activate ATM and c-MET, inactivate mTOR, AKT, and p70 S6K, e...

Full description

Bibliographic Details
Main Authors: Laurence Booth, Cameron West, Daniel Von Hoff, Paul Dent
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Oncology
Subjects:
autophagy
GZ17-6.02
sarcoma
doxorubicin
CD95
death receptor
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.01331/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.01331/full

Similar Items